An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
1 Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA. Electronic address: sibleyd@ninds.nih.gov.
2 Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.
3 Computational Chemistry and Molecular Biophysics Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Drive, Baltimore, MD 21224, USA. Electronic address: lei.shi2@nih.gov.
1 Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA. Electronic address: sibleyd@ninds.nih.gov.
2 Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Drive, Bethesda, MD 20892, USA.
3 Computational Chemistry and Molecular Biophysics Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, National Institutes of Health, 333 Cassell Drive, Baltimore, MD 21224, USA. Electronic address: lei.shi2@nih.gov.
Rational drug design for G protein-coupled receptors (GPCRs) remains a challenging area. A new study from the Xu, Roth, and Zhang groups provides a complete set of active structures for the entire dopamine receptor family bound with rotigotine that will aid in designing selective agonists for these important therapeutic targets.
Declaration of interests The authors declare no competing interests.
Figures
Figure 1.
D2-like receptors have more divergent…
Figure 1.
D2-like receptors have more divergent binding pockets than D1-like receptors. (A) An overview…
Figure 1.
D2-like receptors have more divergent binding pockets than D1-like receptors. (A) An overview of the rotigotine bound DAR-G protein complexes, using the D2R-Gi protein structure as an example. The ligand binding pocket is indicated by a magenta box. In the zoom-in views of the ligand binding pocket, (B) and (C), the structures of D1-like and D2-like receptors are overlaid, respectively. The binding site residues are determined based on sidechain atoms within 4.7Å proximity to rotigotine bound in any of the five structures. Conserved residues shared among DARs are depicted in dark grey, while residues conserved within either the D1-like or D2-like subgroup are depicted in light grey. Divergent residues within D2-like subgroup are highlighted in cyan, with the residue identities labeled as D2R/D3R/D4R. The bound rotigotine molecule is in sphere representation.
Allen JA and Roth BL (2011) Strategies to discover unexpected targets for drugs active at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 51:117–44. doi: 10.1146/annurev-pharmtox-010510-100553
-
DOI
-
PubMed
Xu P, Huang S, Krumm BE, Zhuang Y, Mao C, Zhang Y, Wang Y, Huang XP, Liu YF, He X, Li H, Yin W, Jiang Y, Zhang Y, Roth BL and Xu HE (2023) Structural genomics of the human dopamine receptor system. Cell Res. doi: 10.1038/s41422-023-00808-0
-
DOI
-
PMC
-
PubMed
Sun B, Feng D, Chu ML, Fish I, Lovera S, Sands ZA, Kelm S, Valade A, Wood M, Ceska T, Kobilka TS, Lebon F and Kobilka BK (2021) Crystal structure of dopamine D1 receptor in complex with G protein and a non-catechol agonist. Nat Commun 12:3305. doi: 10.1038/s41467-021-23519-9
-
DOI
-
PMC
-
PubMed
Teng X, Chen S, Nie Y, Xiao P, Yu X, Shao Z and Zheng S (2022) Ligand recognition and biased agonism of the D1 dopamine receptor. Nat Commun 13:3186. doi: 10.1038/s41467-022-30929-w
-
DOI
-
PMC
-
PubMed
Sibley DR, Luderman KD, Free RB and Shi L (2021) Novel Cryo-EM structures of the D1 dopamine receptor unlock its therapeutic potential. Signal Transduct Target Ther 6:205. doi: 10.1038/s41392-021-00630-3
-
DOI
-
PMC
-
PubMed